

orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 11, 1998. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 11, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On February 19, 1998, from 3:45 p.m. to 5:30 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). The investigational new drug and Phase I and II drug products in process will be presented and recent action on selected new drug applications will be discussed.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 27, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98-2576 Filed 2-2-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/

496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Pseudomonas Exotoxin A-Like Chimeric Immunogens

David J. Fitzgerald (NCI)

Serial No. 60,052,375 filed 11 Jul 97

(Assignee: United States Government)

Licensing Contact: Robert Benson, 301/496-7056 ext. 267

This invention concerns a recombinantly made chimeric immunogen comprising a non-toxic version of Pseudomonas exotoxin A (PE) in which the Ib domain is replaced with a non-native epitope. This immunogen can be used as a vaccine, either as a protein or as DNA, and can elicit humoral, cell-mediated and secretory immune responses against the non-native epitope. The non-native epitope fits into the cysteine-cysteine loop of the Ib domain, thus epitopes normally part of a loop are held in their natural conformation. Chimeric immunogens comprising the V3 loop of the HIV-1 env protein have been shown to raise, in rabbits, neutralizing antibodies against clinical isolates of HIV, some cross-protection was seen. Anti-V3 IgA antibodies were raised upon mucosal administration. The claims cover: (a) Chimeric immunogens, (b) nucleic acids encoding chimeric immunogens, (c) antibodies raised against chimeric immunogens, (d) vaccines and methods of immunization.

Pseudomonas Exotoxin A-Like Chimeric Immunogens for Mucosal Immunity

David J. Fitzgerald (NCI) and Randall J. Mrsny (Genentech Corp.)

Serial No. 60/056,924 filed 11 Jul 97

(Assignees: United States Government and Genentech Corporation)

Licensing Contact: Robert Benson, 301/496-7056 ext. 267

This invention claims the use of the chimeric immunogens claimed in 60/052,375 to elicit a secretory IgA-mediated immune response. The inventors have shown that parenteral and mucosal administration of the HIV V3 loop/Exotoxin A chimeric immunogen to rabbits raises both a humoral and cell-mediated immune response against HIV. Both parenteral and mucosal administration result in IgG and IgA antibodies being raised, mucosal administration resulted in higher IgA production. Compositions comprising secretory IgA reactive with the non-native epitope are also claimed.

Pin*Point—A Method To Determine Transcription Factor Binding Site In Vivo

Jay Chung (NHLBI)

Serial Nos. 08/826,622 and 08/825,664 filed 03 Apr 97

Licensing Contact: Joseph Contrera, 301/496-7056 ext. 244

Transcription factors play central roles in many disease processes: cancer, AIDS, developmental aberrations, aging and obesity, just to name a few. Therefore, understanding these disease processes and finding cures for them will be greatly assisted by the capability to determine the genes targeted by the transcription factors in vivo. Toward this end, we have designed an in vivo method (PIN*POINT) ProteIN POSition Identification with Nuclease Tail). In this method, a fusion protein composed of a chosen protein linked to a non-sequence specific nuclease is expressed in vivo and the binding of the protein to DNA is made detectable by the nuclease-induced cleavage near the binding site. For example, p53-nuclease fusion protein expressed in vivo will bind to the p53 binding site and mark it by cleaving the DNA near it. The cleavage site can be identified by a number of techniques currently available. A mammalian expression vector designed to express a fusion protein consisting of a polypeptide of one's choice and the nuclease is available as are expression vectors for Sp1 nuclease, TBP (TATA binding protein)-nuclease (for identifying promoters of genes) and other transcription factors. PIN*POINT is described in a paper soon to be published by Lee et al., (1998) PNAS 95, 060-974.

Dated: January 23, 1998.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 98-2561 Filed 2-2-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Heart, Lung, and Blood Institute Special Emphasis Panel (SEP) meeting: